- Home
- CBFV vs KZIA Comparison
CBFV vs KZIA Comparison
Compare CBFV & KZIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CBFV | KZIA |
|---|---|---|
| Founded | 1901 | 1994 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.9M | 161.5M |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | CBFV | KZIA |
|---|---|---|
| Price | $36.99 | $9.94 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $36.00 | $17.67 |
| AVG Volume (30 Days) | 8.6K | ★ 1.7M |
| Earning Date | 01-28-2026 | 12-26-2025 |
| Dividend Yield | ★ 2.85% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.51 | N/A |
| Revenue | ★ $40,244,000.00 | $1,199,108.00 |
| Revenue This Year | $10.71 | N/A |
| Revenue Next Year | $12.52 | N/A |
| P/E Ratio | $71.72 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $26.01 | $2.86 |
| 52 Week High | $36.90 | $18.20 |
Technical Indicators
Market Signals| Indicator | CBFV | KZIA |
|---|---|---|
| Relative Strength Index (RSI) | 67.07 | 48.56 |
| Support Level | $35.71 | $8.91 |
| Resistance Level | $36.65 | $12.20 |
| Average True Range (ATR) | 0.85 | 2.42 |
| MACD | 0.13 | -0.51 |
| Stochastic Oscillator | 97.98 | 23.97 |
Price Performance
Historical ComparisonAbout CBFV CB Financial Services Inc.
CB Financial Services Inc operates as a bank holding company. The company conducts its operations through its wholly-owned subsidiary, Community Bank, a Pennsylvania-chartered commercial bank. The Bank offers products and services related to residential and commercial real estate loans, commercial and industrial loans, and consumer loans, as well as a range of deposit products for individuals and businesses in its market area. It operates in two operating units namely Community Banking and Insurance brokerage service segment. The bank generates its revenue in the form of interest.
About KZIA Kazia Therapeutics Limited
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.